A meta-study being published in the upcoming issue of the journal Neuroendocrinology Letters, and published online ahead of print by the U.S. National Institute of Health, has found that cannabinoid deficiency may play a role in migraines, fribromyalgia, irritable bowel syndrome and other medical conditions, indicating that cannabinoid intake may provide a treatment option for these ailments.
For the study; “Available literature was reviewed, including searches via the National Library of medicine database and other sources.”
In doing so, it was found that; “research has confirmed that underlying endocannabinoid deficiencies indeed play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions. Clinical experience is bearing this out. Further research and especially, clinical trials will further demonstrate the usefulness of medical cannabis. As legal barriers fall and scientific bias fades this will become more apparent.”
The study can be found by clicking here.